ArticleFrontiers in oncology2026
Knowledge, attitudes, and decision-making regarding hyperbaric oxygen-assisted cancer treatment among related healthcare professionals.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study aimed to evaluate the knowledge, attitudes, and clinical decision-making of healthcare professionals in hyperbaric oxygen therapy (HBOT) units and oncology specialties regarding HBOT as an adjunctive cancer treatment. Methods: A cross-sectional survey was conducted between February, 2024 and February, 2025. Data were collected using a structured questionnaire, which included sections on demographic characteristics and assessed participants' knowledge, attitudes, and practices (KAP) related to hyperbaric oxygen-assisted cancer therapy. The KAP scores were calculated to quantify the respondents' familiarity with and perspectives on the treatment. Results: Of 202 valid questionnaires, 58.91% were physicians. The majority (63.86%) had over 15 years of clinical experience, and 79.70% reported prior HBOT training in oncology. The mean scores were 52.87 ± 12.21 for knowledge, 41.24 ± 5.92 for attitudes, and 22.40 ± 2.38 for decision-making. Analysis indicated that knowledge positively influenced attitudes (β=0.393, P = 0.013) and decision-making (β = 0.159, P = 0.018), while attitudes significantly impacted decision-making (β = 0.318, P = 0.012). Knowledge indirectly affected decision-making via attitude (β = 0.125, P = 0.004). Conclusions: Healthcare professionals working in HBOT units and oncology-related specialties demonstrated a generally adequate level of knowledge, positive attitudes, and a proactive approach toward the use of HBOT as an adjunctive cancer treatment, with attitude emerging as a key mediator linking knowledge to clinical decision-making. These findings highlight the importance of targeted educational interventions aimed at strengthening both knowledge and attitudes, which may in turn enhance evidence-based clinical decision-making and support the broader integration of HBOT into oncologic care pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.